Overview

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

The main purpose is to learn if adding bevacizumab to standard chemotherapy and trastuzumab to treat HER2-positive breast cancer will affect heart function. This study will evaluate: - How bevacizumab, given with chemotherapy, and then bevacizumab given with trastuzumab after surgery, will affect breast tumors - Side effects from adding bevacizumab to chemotherapy and trastuzumab - Whether adding bevacizumab to chemotherapy and trastuzumab for breast cancer will affect the heart - If receiving bevacizumab will have any effect on how patients recover from surgery

Phase:

Phase 2

Details

Lead Sponsor:

NSABP Foundation Inc

Collaborators:

Genentech, Inc.
International Drug Development Institute

Treatments:

Bevacizumab
Cyclophosphamide
Docetaxel
Epirubicin
Trastuzumab